CytomX Therapeutics Announces Board and Executive Changes
Ticker: CTMX · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
CytomX board shakeup and comp changes announced June 12.
AI Summary
CytomX Therapeutics, Inc. announced on June 12, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: low — This filing primarily reports on routine corporate governance changes and executive compensation, which typically carry low immediate risk.
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- June 12, 2024 (date) — Date of earliest event reported
- 151 Oyster Point Blvd Suite 400 South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
What specific items are being reported in this 8-K filing?
This 8-K filing reports on the Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers, and Compensatory Arrangements of Certain Officers.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 12, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 151 Oyster Point Blvd Suite 400 South San Francisco, California 94080.
What is the company's telephone number?
The company's telephone number, including area code, is 650 515-3185.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 721 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-06-17 16:35:31
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Glo
Filing Documents
- d831468d8k.htm (8-K) — 24KB
- 0001193125-24-162652.txt ( ) — 147KB
- ctmx-20240612.xsd (EX-101.SCH) — 3KB
- ctmx-20240612_lab.xml (EX-101.LAB) — 18KB
- ctmx-20240612_pre.xml (EX-101.PRE) — 11KB
- d831468d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYTOMX THERAPEUTICS, INC. Date: June 17, 2024 By: /s/ Lloyd Rowland Lloyd Rowland SVP, General Counsel